Epitope-Chimeric H5 Vaccine for Cross-Clade Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional H5N1 vaccines are ineffective against antigenically distinct H5N1 strains due to variations in hemagglutinin sequences, leading to limited cross-clade protection, and the development of effective pre-pandemic vaccines is hindered by time-consuming and costly production methods.
Innovation Solution
A monovalent H5 vaccine strain is developed using hemagglutinin (HA) engineering to elicit cross-clade protection, incorporating specific mutations in the H5 protein to create an epitope-chimeric H5 protein expressed through a reverse genetics influenza virus, which can be neutralized by multiple monoclonal antibodies and induces broad immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional HA-based H5N1 vaccines are used, then they provide protection against specific H5N1 strains, but they fail to provide cross-clade protection against antigenically distinct H5N1 strains
Solution Approach 1:
The patent applies local quality by making specific amino acid substitutions at key epitope positions (131, 141, 155, 156, 189) in the H5 hemagglutinin protein while keeping the rest of the protein sequence unchanged. This localized modification approach allows the vaccine to maintain strain-specific protection while gaining cross-clade recognition capabilities through targeted epitope engineering.
Solution Approach 2:
The patent creates a universal H5N1 vaccine candidate that can protect against multiple clades (1, 2, 7) simultaneously. The engineered H5 protein with specific epitope substitutions functions as a multi-functional antigen that elicits cross-clade protective immunity, making a single vaccine formulation effective against diverse H5N1 strains without requiring separate vaccines for each clade.
2Adaptability or versatility
If a cocktail of multiple antigenically different virus strains is used to elicit broad protection, then cross-clade protection is improved, but the propagation and development becomes time-consuming, technique-demanding and expensive
Solution Approach 1:
The patent merges multiple clade-specific epitopes into a single H5 hemagglutinin protein sequence. Instead of requiring separate propagation and formulation of multiple virus strains, the engineered H5 protein combines protective epitopes from different clades into one molecular entity that can be produced as a single vaccine strain, dramatically simplifying manufacturing while maintaining broad protection.
Solution Approach 2:
The single engineered H5N1 vaccine strain performs the function of multiple vaccine strains by incorporating cross-reactive epitopes from different clades. This universal vaccine approach eliminates the need for complex multi-strain formulations, reducing manufacturing steps, technical requirements, and costs while providing equivalent broad protection.
3Adaptability or versatility
If HA sequence variations are present in different H5N1 clades, then antigenic diversity is increased, but cross-protective immunity is reduced
Solution Approach 1:
The patent addresses HA sequence variations by making targeted amino acid substitutions at specific epitope positions (131, 141, 155, 156, 189) that are known to vary across clades. This local modification strategy maintains the overall antigenic diversity needed for clade-specific recognition while correcting key variable positions to enhance cross-clade antibody binding and protective immunity.
Data Source
AI summary
The present invention relates to a monovalent H5N1 vaccine. More specifically, the present invention relates to the development of a monovalent H5 vaccine strain using hemagglutinin (HA) engineering to elicit cross-clade protection. The present invention also relates to an epitope-chimeric H5 and to a reverse genetics (RG) influenza virus expressing the epitope-chimeric H5.